Andò Giuseppe, Cortese Bernardo, Russo Filippo, Rothenbühler Martina, Frigoli Enrico, Gargiulo Giuseppe, Briguori Carlo, Vranckx Pascal, Leonardi Sergio, Guiducci Vincenzo, Belloni Flavia, Ferrari Fabio, de la Torre Hernandez Jose Maria, Curello Salvatore, Liistro Francesco, Perkan Andrea, De Servi Stefano, Casu Gavino, Dellavalle Antonio, Fischetti Dionigi, Micari Antonio, Loi Bruno, Mangiacapra Fabio, Russo Nunzio, Tarantino Fabio, Saia Francesco, Heg Dik, Windecker Stephan, Jüni Peter, Valgimigli Marco
Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino," University of Messina, Messina, Italy.
Department of Medicine, Ospedale Fate bene Fratelli, Milano, Italy.
J Am Coll Cardiol. 2017 May 11. doi: 10.1016/j.jacc.2017.02.070.
It remains unclear whether radial access (RA), compared with femoral access (FA), mitigates the risk of acute kidney injury (AKI).
The authors assessed the incidence of AKI in patients with acute coronary syndrome (ACS) enrolled in the MATRIX-Access (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox) trial.
Among 8,404 patients, 194 (2.3%) were excluded due to missing creatinine values, no or an incomplete coronary angiogram, or previous dialysis. The primary AKI-MATRIX endpoint was AKI, defined as an absolute (>0.5 mg/dl) or a relative (>25%) increase in serum creatinine (sCr).
AKI occurred in 634 patients (15.4%) with RA and 712 patients (17.4%) with FA (odds ratio [OR]: 0.87; 95% confidence interval [CI]: 0.77 to 0.98; p = 0.0181). A >25% sCr increase was noted in 633 patients (15.4%) with RA and 710 patients (17.3%) with FA (OR: 0.87; 95% CI: 0.77 to 0.98; p = 0.0195), whereas a >0.5 mg/dl absolute sCr increase occurred in 175 patients (4.3%) with RA versus 223 patients (5.4%) with FA (OR: 0.77; 95% CI: 0.63 to 0.95; p = 0.0131). By implementing the Kidney Disease Improving Global Outcomes criteria, AKI was 3-fold less prevalent and trended lower with RA (OR: 0.85; 95% CI: 0.70 to 1.03; p = 0.090), with stage 3 AKI occurring in 28 patients (0.68%) with RA versus 46 patients (1.12%) with FA (p = 0.0367). Post-intervention dialysis was needed in 6 patients (0.15%) with RA and 14 patients (0.34%) with FA (p = 0.0814). Stratified analyses suggested greater benefit with RA than FA in patients at greater risk for AKI.
In ACS patients who underwent invasive management, RA was associated with a reduced risk of AKI compared with FA. (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX [MATRIX]; NCT01433627).
与股动脉入路(FA)相比,桡动脉入路(RA)是否能降低急性肾损伤(AKI)的风险仍不明确。
作者评估了纳入MATRIX - Access(通过桡动脉入路部位和血管造影剂的系统应用最小化不良出血事件)试验的急性冠状动脉综合征(ACS)患者中AKI的发生率。
在8404例患者中,194例(2.3%)因肌酐值缺失、未进行或冠状动脉造影不完整或既往透析而被排除。主要的AKI - MATRIX终点是AKI,定义为血清肌酐(sCr)绝对升高(>0.5mg/dl)或相对升高(>25%)。
RA组634例患者(15.4%)发生AKI,FA组712例患者(17.4%)发生AKI(比值比[OR]:0.87;95%置信区间[CI]:0.77至0.98;p = 0.0181)。RA组633例患者(15.4%)sCr升高>25%,FA组710例患者(17.3%)sCr升高>25%(OR:0.87;95%CI:0.77至0.98;p = 0.0195),而RA组175例患者(4.3%)sCr绝对升高>0.5mg/dl,FA组223例患者(5.4%)sCr绝对升高>0.5mg/dl(OR:0.77;95%CI:0.63至0.95;p = 0.0131)。采用改善全球肾脏病预后组织标准,AKI的患病率在RA组降低了3倍且有下降趋势(OR:0.85;95%CI:0.70至1.03;p = 0.090),RA组28例患者(0.68%)发生3期AKI,FA组46例患者(1.12%)发生3期AKI(p = 0.0367)。RA组6例患者(0.15%)和FA组14例患者(0.34%)需要干预后透析(p = 0.0814)。分层分析表明,在发生AKI风险较高的患者中,RA组比FA组获益更大。
在接受侵入性治疗的ACS患者中,与FA相比,RA与AKI风险降低相关。(通过桡动脉入路部位和血管造影剂的系统应用最小化不良出血事件[MATRIX];NCT01433627)